Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CSII's Cash to Debt is ranked higher than
94% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. CSII: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CSII' s Cash to Debt Range Over the Past 10 Years
Min: 1.11  Med: 369.07 Max: No Debt
Current: No Debt
Equity to Asset 0.80
CSII's Equity to Asset is ranked higher than
75% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CSII: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
CSII' s Equity to Asset Range Over the Past 10 Years
Min: -1.4  Med: 0.49 Max: 0.94
Current: 0.8
-1.4
0.94
F-Score: 4
Z-Score: 7.21
M-Score: -3.02
WACC vs ROIC
20.62%
-92.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -26.32
CSII's Operating margin (%) is ranked lower than
66% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. CSII: -26.32 )
Ranked among companies with meaningful Operating margin (%) only.
CSII' s Operating margin (%) Range Over the Past 10 Years
Min: -215.75  Med: -21.58 Max: 3.82
Current: -26.32
-215.75
3.82
Net-margin (%) -26.42
CSII's Net-margin (%) is ranked lower than
66% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.79 vs. CSII: -26.42 )
Ranked among companies with meaningful Net-margin (%) only.
CSII' s Net-margin (%) Range Over the Past 10 Years
Min: -182.94  Med: -23.14 Max: 13.13
Current: -26.42
-182.94
13.13
ROE (%) -35.00
CSII's ROE (%) is ranked lower than
73% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. CSII: -35.00 )
Ranked among companies with meaningful ROE (%) only.
CSII' s ROE (%) Range Over the Past 10 Years
Min: -99.5  Med: -48.55 Max: 10
Current: -35
-99.5
10
ROA (%) -28.28
CSII's ROA (%) is ranked lower than
72% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.56 vs. CSII: -28.28 )
Ranked among companies with meaningful ROA (%) only.
CSII' s ROA (%) Range Over the Past 10 Years
Min: -58.12  Med: -29.71 Max: 6.68
Current: -28.28
-58.12
6.68
ROC (Joel Greenblatt) (%) -98.37
CSII's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. CSII: -98.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CSII' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4509.29  Med: -228.49 Max: 88.2
Current: -98.37
-4509.29
88.2
Revenue Growth (3Y)(%) 8.00
CSII's Revenue Growth (3Y)(%) is ranked higher than
68% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. CSII: 8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CSII' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -13.20 Max: 23.9
Current: 8
0
23.9
EBITDA Growth (3Y)(%) 6.20
CSII's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. CSII: 6.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CSII' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -42.20 Max: 79.4
Current: 6.2
0
79.4
EPS Growth (3Y)(%) 3.80
CSII's EPS Growth (3Y)(%) is ranked higher than
54% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. CSII: 3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CSII' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: -11.90 Max: 81.2
Current: 3.8
-66.2
81.2
» CSII's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CSII Guru Trades in Q1 2015

Jim Simons 66,000 sh (+331.32%)
Mairs and Power 118,422 sh (unchged)
John Burbank Sold Out
Steven Cohen 217,800 sh (-48.87%)
» More
Q2 2015

CSII Guru Trades in Q2 2015

Paul Tudor Jones 8,400 sh (New)
Mario Gabelli 25,000 sh (New)
Steven Cohen 367,136 sh (+68.57%)
Mairs and Power 134,182 sh (+13.31%)
Jim Simons Sold Out
» More
Q3 2015

CSII Guru Trades in Q3 2015

Jim Simons 126,539 sh (New)
Mairs and Power 207,632 sh (+54.74%)
Mario Gabelli 33,500 sh (+34.00%)
Paul Tudor Jones Sold Out
Steven Cohen 42,800 sh (-88.34%)
» More
Q4 2015

CSII Guru Trades in Q4 2015

Jim Simons 167,200 sh (+32.13%)
Mairs and Power 246,202 sh (+18.58%)
Mario Gabelli 35,200 sh (+5.07%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CSII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Cardiovascular Systems Inc

Mairs & Power Small Cap Fund Comments on Cardiovascular Systems - Oct 20, 2014

During the quarter, the Fund added medical device maker Cardiovascular Systems (CSII), one of the few remaining small public medical device companies based in the Twin Cities. The company has a strong position in treating peripheral arterial disease with its proprietary atherectomy equipment. A recent approval in significantly calcified coronary arteries opens up a substantial new market opportunity that the company is working hard to commercialize.



From Mairs & Power Small Cap Fund Q3 2014 Commentary.



Check out Bill Frels latest stock trades

Ratios

vs
industry
vs
history
P/B 3.66
CSII's P/B is ranked lower than
63% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. CSII: 3.66 )
Ranked among companies with meaningful P/B only.
CSII' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 5.34 Max: 14.5
Current: 3.66
0.18
14.5
P/S 2.38
CSII's P/S is ranked higher than
56% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. CSII: 2.38 )
Ranked among companies with meaningful P/S only.
CSII' s P/S Range Over the Past 10 Years
Min: 0.24  Med: 2.17 Max: 7.39
Current: 2.38
0.24
7.39
Current Ratio 4.03
CSII's Current Ratio is ranked higher than
69% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. CSII: 4.03 )
Ranked among companies with meaningful Current Ratio only.
CSII' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 4.08 Max: 17.17
Current: 4.03
1.27
17.17
Quick Ratio 3.38
CSII's Quick Ratio is ranked higher than
71% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. CSII: 3.38 )
Ranked among companies with meaningful Quick Ratio only.
CSII' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 3.67 Max: 17.17
Current: 3.38
1.18
17.17
Days Inventory 143.25
CSII's Days Inventory is ranked lower than
53% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 134.42 vs. CSII: 143.25 )
Ranked among companies with meaningful Days Inventory only.
CSII' s Days Inventory Range Over the Past 10 Years
Min: 37.97  Med: 112.49 Max: 124.02
Current: 143.25
37.97
124.02
Days Sales Outstanding 52.01
CSII's Days Sales Outstanding is ranked higher than
76% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 70.19 vs. CSII: 52.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
CSII' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.75  Med: 58.75 Max: 105.79
Current: 52.01
51.75
105.79
Days Payable 79.57
CSII's Days Payable is ranked higher than
58% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 64.85 vs. CSII: 79.57 )
Ranked among companies with meaningful Days Payable only.
CSII' s Days Payable Range Over the Past 10 Years
Min: 81.57  Med: 107.08 Max: 116.18
Current: 79.57
81.57
116.18

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.86
CSII's Price/Net Cash is ranked higher than
59% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 14.74 vs. CSII: 11.86 )
Ranked among companies with meaningful Price/Net Cash only.
CSII' s Price/Net Cash Range Over the Past 10 Years
Min: 0.54  Med: 10.02 Max: 231.2
Current: 11.86
0.54
231.2
Price/Net Current Asset Value 5.34
CSII's Price/Net Current Asset Value is ranked higher than
55% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. CSII: 5.34 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CSII' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.53  Med: 6.58 Max: 27.54
Current: 5.34
0.53
27.54
Price/Tangible Book 3.80
CSII's Price/Tangible Book is ranked lower than
51% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 3.66 vs. CSII: 3.80 )
Ranked among companies with meaningful Price/Tangible Book only.
CSII' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.52  Med: 5.60 Max: 12.81
Current: 3.8
0.52
12.81
Price/Median PS Value 1.10
CSII's Price/Median PS Value is ranked lower than
58% of the 248 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. CSII: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
CSII' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 1.13 Max: 3.21
Current: 1.1
0.32
3.21
Earnings Yield (Greenblatt) (%) -12.68
CSII's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. CSII: -12.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CSII' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.68  Med: 32.00 Max: 5408.1
Current: -12.68
-12.68
5408.1

More Statistics

Revenue(Mil) $181
EPS $ -1.49
Beta2.51
Short Percentage of Float9.00%
52-Week Range $7.50 - 33.37
Shares Outstanding(Mil)32.70

Analyst Estimate

Jun16 Jun17 Jun18
Revenue(Mil) 170 187 215
EPS($) -1.70 -1.38 -0.04
EPS without NRI($) -1.70 -1.38 -0.04

Business Description

Industry: Medical Devices » Medical Devices
Compare:HKSE:00853, TSE:6960, NAS:SPNC, LSE:CSRT, HKSE:01302, NAS:KTWO » details
Traded in other countries:R7Y1.Germany,
Cardiovascular Systems Inc was incorporated as Replidyne, Inc. in Delaware in 2000. It is a medical technology company. The Company is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases. It treats patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium, the difficult arterial disease to treat. The Company is committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve lives of patients facing this difficult disease state. Its product s include Diamondback 360 Peripheral, Predator 36, Stealth 360, Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral. It competes with Abbott Laboratories, Boston Scientific, Cook Medical, Johnson & Johnson, BARD, and Medtronic. It also competes against manufacturers of atherectomy catheters including Medtronic, Spectranetics, Boston Scientific and Philips. The Company held approximately 46 issued U.S. patents and have approximately 39U.S.patent applications pending, as well as approximately 203 issued or granted foreign patents and approximately 148 foreign patent applications, each of which corresponds to aspects of its U.S. patents and applications. The Company have received 18 federal registrations in the U.S. Patent and Trademark Office of certain marks, including Diamondback, a first CSI, second CSI, Predator 360, Stealth 360, a first CSI logo, a second CSI logo, Lumen Library, Viper Wire, Viper Wire Advance, Viper slide, Viper Track, Viper Caddy, Stealth 360, a first Diamondback 360, a second Diamondback 360, Diamondback 360 (Stylized) Logo, and Stay A Step Ahead of PAD.
» More Articles for CSII

Headlines

Articles On GuruFocus.com
Stocks Bill Frels Keeps On Buying Nov 17 2015 
Mairs & Power Small Cap Fund Comments on Cardiovascular Systems Oct 20 2014 
Mairs & Power Small Cap Fund Q3 2014 Commentary Oct 20 2014 
Weekly CEO Sells Highlight: Google Inc, Infromatica Corp, Deckers Outdoor Corp and Cardiovascular Sy Aug 14 2011 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 13,170 Shares Nov 19 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 39,330 Shares Nov 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 12 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) CFO Laurence L Betterley sells 5,663 Shares May 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) May 14 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Feb 12 2010 

More From Other Websites
Boston Scientific (BSX) Tops Q1 Earnings, Raises Guidance Apr 27 2016
Can The Uptrend Continue for Cardiovascular Systems (CSII)? Apr 27 2016
Over 70% of Americans Would Buy A Health Tracking Device if Clinically Accurate Apr 20 2016
Cardiovascular Systems to Webcast Fiscal 2016 Third-Quarter Earnings Conference Call Wednesday, May... Apr 20 2016
Cardiovascular Systems to Webcast Fiscal 2016 Third-Quarter Earnings Conference Call Wednesday, May... Apr 20 2016
Deadline Alert: Law Offices of Howard G. Smith Reminds Cardiovascular Systems Inc. Investors of... Apr 12 2016
DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving... Apr 11 2016
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Apr 11 2016
STOCK ALERT: Rosen Law Firm Reminds Cardiovascular Systems Inc. Investors of Important April 12,... Apr 08 2016
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Apr 08 2016
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Apr 08 2016
April 12 Deadline Alert: GPM Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class... Apr 07 2016
Biotricity (BTCY) Capitalizes on Healthcare IoT with Clear Pathway to Commercialization Apr 06 2016
Cardiovascular Systems to Present at the 15th Annual Needham Healthcare Conference Apr 06 2016
Cardiovascular Systems to Present at the 15th Annual Needham Healthcare Conference Apr 06 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cardiovascular Systems, Inc. of Class... Apr 05 2016
Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Apr 05 2016
CARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 05 2016
DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from... Apr 04 2016
Important Lead Plaintiff Deadline Reminder for Cardiovascular Systems Shareholders From Kessler... Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK